Alterity Therapeutics Limited Stock OTC Markets
Stocks
PRNAF
AU0000043945
Biotechnology & Medical Research
OTC Markets Traded|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0550 USD | +450.00% |
|
-.--% | -82.40% |
| Market Cap | 87.53M 76.53M 70.6M 64.9M 123M 8.42B 125M 843M 331M 4.12B 329M 322M 14.19B | P/E 2026 * |
-0.34x | P/E 2027 * | -0.33x |
|---|---|---|---|---|---|
| Enterprise Value | 42.34M 37.02M 34.15M 31.39M 59.48M 4.07B 60.5M 408M 160M 1.99B 159M 156M 6.86B | EV / Sales 2026 * |
16.5x | EV / Sales 2027 * | 38.9x |
| Free-Float |
91.76% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Alterity Therapeutics Limited
| 1 day | +450.00% | ||
| 6 months | -89.81% | ||
| Current year | -82.40% |
| 1 week | 0 |  | 0.45 |
| 1 month | 0 | | 0.45 |
| Current year | 0 | | 0.54 |
| 1 year | 0 | | 0.54 |
| 3 years | 0 | | 0.7 |
| 5 years | 0 | | 2.36 |
| 10 years | 0 | | 4.75 |
| Manager | Title | Age | Since |
|---|---|---|---|
David Stamler
CEO | Chief Executive Officer | 65 | 07/01/2021 |
Abby Niven
DFI | Director of Finance/CFO | - | 30/09/2024 |
| Chief Tech/Sci/R&D Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Peter Marks
BRD | Director/Board Member | 70 | 29/07/2005 |
Lawrence Gozlan
BRD | Director/Board Member | 47 | 08/08/2011 |
David Stamler
BRD | Director/Board Member | 65 | 21/11/2025 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +450.00% | -.--% | - | - | 87.53M | |
| -1.70% | -1.79% | +0.42% | +5.73% | 50.35B | |
| -0.29% | -2.81% | +387.81% | +591.82% | 39.21B | |
| -0.49% | +1.48% | +31.16% | -6.46% | 34.52B | |
| +1.53% | +3.11% | +15.41% | +58.54% | 34.6B | |
| +1.68% | -0.62% | +3.30% | +27.34% | 27.05B | |
| +1.13% | -3.11% | - | - | 16.68B | |
| -1.29% | -0.52% | +69.24% | +117.60% | 15.11B | |
| -0.55% | +0.17% | +13.99% | +17.33% | 13.85B | |
| +2.45% | +3.99% | +18.20% | -30.12% | 13.18B | |
| Average | +45.25% | +0.94% | +67.44% | +97.72% | 27.17B | |
| Weighted average by Cap. | +0.20% | +0.83% | +80.77% | +121.37% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 2.57M 2.25M 2.07M 1.9M 3.61M 247M 3.67M 24.73M 9.7M 121M 9.65M 9.43M 416M | 1.2M 1.05M 968K 890K 1.69M 115M 1.71M 11.56M 4.53M 56.45M 4.51M 4.41M 195M |
| Net income | -14.64M -12.8M -11.81M -10.86M -20.57M -1.41B -20.92M -141M -55.32M -689M -54.99M -53.79M -2.37B | -29.66M -25.93M -23.92M -21.99M -41.67M -2.85B -42.38M -286M -112M -1.39B -111M -109M -4.81B |
| Net Debt | -45.19M -39.51M -36.45M -33.5M -63.48M -4.35B -64.57M -435M -171M -2.13B -170M -166M -7.33B | -40.88M -35.74M -32.97M -30.31M -57.43M -3.93B -58.41M -394M -154M -1.92B -154M -150M -6.63B |
| Date | Price | Change | Volume |
|---|
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- ATH Stock
- PRNAF Stock
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
